Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.75
-0.16 (-2.71%)
At close: Dec 5, 2025, 4:00 PM EST
5.74
-0.01 (-0.17%)
After-hours: Dec 5, 2025, 6:15 PM EST
Karyopharm Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 142.53 | 145.24 | 146.03 | 157.07 | 209.82 | 108.09 | Upgrade
|
| Revenue Growth (YoY) | -3.98% | -0.55% | -7.03% | -25.14% | 94.12% | 164.31% | Upgrade
|
| Cost of Revenue | -6.18 | 6.01 | 4.94 | 5.21 | 3.4 | 2.71 | Upgrade
|
| Gross Profit | 148.71 | 139.23 | 141.09 | 151.86 | 206.42 | 105.38 | Upgrade
|
| Selling, General & Admin | 109.63 | 115.44 | 131.88 | 145.4 | 143.85 | 126.42 | Upgrade
|
| Research & Development | 143.23 | 143.23 | 138.75 | 148.66 | 160.84 | 150.81 | Upgrade
|
| Operating Expenses | 252.86 | 258.67 | 270.63 | 294.06 | 304.69 | 277.23 | Upgrade
|
| Operating Income | -104.14 | -119.44 | -129.54 | -142.2 | -98.27 | -171.85 | Upgrade
|
| Interest Expense | -44.43 | -37.42 | -23.82 | -25 | -26.05 | -27.14 | Upgrade
|
| Interest & Investment Income | 3.65 | 7.4 | 10.94 | 2.36 | 0.58 | 2.82 | Upgrade
|
| Other Non Operating Income (Expenses) | 20.31 | 28.4 | -0.36 | -0.08 | -0.09 | 0.21 | Upgrade
|
| EBT Excluding Unusual Items | -124.62 | -121.07 | -142.78 | -164.92 | -123.82 | -195.96 | Upgrade
|
| Other Unusual Items | - | 44.7 | - | - | - | - | Upgrade
|
| Pretax Income | -124.62 | -76.37 | -142.78 | -164.92 | -123.82 | -195.96 | Upgrade
|
| Income Tax Expense | 0 | 0.06 | 0.32 | 0.37 | 0.27 | 0.31 | Upgrade
|
| Net Income | -124.62 | -76.42 | -143.1 | -165.29 | -124.09 | -196.27 | Upgrade
|
| Net Income to Common | -124.62 | -76.42 | -143.1 | -165.29 | -124.09 | -196.27 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 8 | 8 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 8 | 8 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 7.52% | 11.02% | 39.51% | 8.85% | 4.41% | 16.28% | Upgrade
|
| EPS (Basic) | -14.60 | -9.41 | -18.79 | -30.28 | -24.75 | -40.87 | Upgrade
|
| EPS (Diluted) | -14.60 | -14.00 | -18.79 | -30.30 | -24.75 | -40.87 | Upgrade
|
| Free Cash Flow | -89.3 | -127.63 | -92.72 | -149.67 | -107.33 | -160.38 | Upgrade
|
| Free Cash Flow Per Share | -10.46 | -15.10 | -12.18 | -27.42 | -21.40 | -33.39 | Upgrade
|
| Gross Margin | 104.34% | 95.86% | 96.62% | 96.68% | 98.38% | 97.50% | Upgrade
|
| Operating Margin | -73.07% | -82.24% | -88.71% | -90.53% | -46.84% | -159.00% | Upgrade
|
| Profit Margin | -87.44% | -52.62% | -97.99% | -105.23% | -59.14% | -181.59% | Upgrade
|
| Free Cash Flow Margin | -62.65% | -87.88% | -63.50% | -95.29% | -51.15% | -148.38% | Upgrade
|
| EBITDA | -103.79 | -119.1 | -129.01 | -141.58 | -97.48 | -170.88 | Upgrade
|
| EBITDA Margin | -72.82% | -82.01% | -88.34% | -90.14% | -46.46% | -158.10% | Upgrade
|
| D&A For EBITDA | 0.36 | 0.34 | 0.53 | 0.62 | 0.79 | 0.97 | Upgrade
|
| EBIT | -104.14 | -119.44 | -129.54 | -142.2 | -98.27 | -171.85 | Upgrade
|
| EBIT Margin | -73.07% | -82.24% | -88.71% | -90.53% | -46.84% | -159.00% | Upgrade
|
| Revenue as Reported | 142.53 | 145.24 | 146.03 | 157.07 | 209.82 | 108.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.